Prof. Dr. Turgay Çelikel
OncologyVerified
- 47+years exp.
English · Turkish
FromPrice on request
Free quote
60 seconds · no obligationView Profile
Chemotherapy & Immunotherapy
Targeted therapy
What targeted therapy is, how small-molecule drugs and monoclonal antibodies block specific cancer mutations, the role of next-generation sequencing, how it compares with chemotherapy and immunotherapy, approximate cycle and monthly costs in Turkey against the UK, US and Germany, expected treatment timelines, monitoring schedules, managing side effects, travel logistics and how to choose an accredited cancer hospital.
A written plan with the surgeon's name and the full price — usually within 24 hours.
- Category
- Chemotherapy & Immunotherapy
- Hospitals
- 2
- Verified
- 1
- Price from
- Price on request
Verified surgeons for Targeted Therapy
1 doctor Compare doctors, ratings and prices — ask any of them for a free quote.
Targeted therapy in Turkey: what it is and how precision oncology works
Targeted therapy is a precision cancer treatment using specialised drugs to identify and attack specific genetic mutations or proteins that enable cancer cells to grow, divide, and spread. Unlike conventional treatments that circulate indiscriminately, targeted medicines focus on distinctive molecular characteristics of malignant cells, sparing most healthy tissues. These treatments include small-molecule inhibitors that enter cancer cells to disrupt internal signals, and monoclonal antibodies that bind to surface antigens. Oncology centres in Turkey utilise targeted therapy alone or with other modalities for solid tumours and blood cancers. For an overview of systemic care, see our guide to oncology treatments in Turkey.
Targeted therapy is not suitable for every cancer. Feasibility depends entirely on identifying an actionable biomarker through molecular pathology or next-generation sequencing. This guide explains how targeted therapies function, what clinical evidence confirms, treatment costs compared with the UK, US, and Germany, who qualifies, and what recovery involves.
How does targeted therapy work against cancer cells?
Cancer cells rely on abnormal signalling pathways to multiply uncontrollably, avoid programmed cell death, and stimulate new blood vessel growth. Targeted drugs block these specific biochemical processes. Small-molecule inhibitors (often ending in “-nib,” such as erlotinib or imatinib) penetrate cell membranes easily to inhibit intracellular enzymes like tyrosine kinases. Monoclonal antibodies (ending in “-mab,” such as trastuzumab or rituximab) attach to external cell receptors, flagging malignant cells for immune destruction or blocking growth factor signals.
Other targeted agents block angiogenesis (such as VEGF inhibitors), depriving tumours of blood supply, or deliver cytotoxic payloads directly to cancer cells via antibody-drug conjugates. Administration involves either daily oral tablets taken at home or intravenous infusions in hospital day-care units lasting 30 to 90 minutes.
Does targeted therapy actually work and what does the clinical evidence show?
Yes, substantial clinical evidence from randomised trials shows that targeted therapy achieves tumour regression, delays disease progression, and extends survival in patients with matching mutations. Regulatory bodies including the European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA) have approved targeted drugs for HER2-positive breast cancer, EGFR-mutant or ALK-rearranged lung cancer, BRAF-mutant melanoma, and chronic myeloid leukaemia.
However, targeted therapies only work when the corresponding molecular target is present. Furthermore, tumours frequently develop secondary resistance over time through bypass pathways. When resistance occurs, oncologists perform repeat biopsies or liquid biopsy blood tests to identify new mutations and adjust the treatment regimen to next-generation targeted compounds.
Targeted therapy cost in Turkey compared with the UK, US and Germany
The figures below outline approximate monthly or per-cycle costs for targeted cancer therapy, not individual hospital quotes. Actual pricing depends on drug patent status (generic, biosimilar, or patented brand), dosage requirements, and the treatment schedule. Hospitals establish confirmed prices following clinical review.
| Country | Approximate monthly or cycle cost range |
|---|---|
| Turkey | €2,500 – €8,000 |
| United Kingdom | €6,000 – €16,000 |
| United States | €10,000 – €28,000 |
| Germany | €5,500 – €15,000 |
Factors influencing total costs include genomic sequencing panels (NGS), cardiac checks, routine blood monitoring, day-care infusion fees, and periodic PET-CT scans. International packages often cover consultations, pathology review, airport transfers, and translation, while drug supplies are billed per cycle based on verified hospital pharmacy charges.
Targeted therapy, chemotherapy or immunotherapy: key differences
Systemic oncology relies on three distinct drug classes. Conventional chemotherapy attacks all rapidly dividing cells, making it widely applicable but causing systemic side effects like hair loss and low blood counts. Targeted therapy acts selectively on specific mutated proteins, producing a different toxicity profile.
| Treatment approach | Best suited to | Typical limits |
|---|---|---|
| Targeted therapy | Cancers with identified actionable driver mutations (e.g. EGFR, HER2, ALK, BRAF) | Requires a positive biomarker; tumour cells can develop secondary resistance |
| Chemotherapy | Rapidly dividing tumours, broad-spectrum systemic control, adjuvant and neoadjuvant care | Affects healthy dividing cells; generalised side effects such as nausea and cytopenia |
| Immunotherapy | Tumours with high PD-L1 expression, high microsatellite instability (MSI-H) or high tumour mutational burden | Variable response rates; risk of immune-related inflammatory toxicities |
Meanwhile, immunotherapy stimulates the patient’s immune system to recognise and destroy malignant cells. In practice, multidisciplinary tumour boards frequently combine targeted drugs with chemotherapy or sequence them with immunotherapy to optimise disease control.
Which cancers and genetic mutations are treated with targeted therapy?
Targeted therapy treats an expanding range of malignancies with identified molecular drivers. In non-small cell lung cancer, targeted agents treat EGFR, ALK, ROS1, and KRAS alterations. In breast oncology, HER2-directed antibodies and CDK4/6 inhibitors are standard treatments. Colorectal cancer frequently responds to EGFR or VEGF blockers, while advanced melanoma with BRAF V600 mutations is treated with combined BRAF and MEK inhibitors.
In haematology, BCR-ABL inhibitors have turned chronic myeloid leukaemia into a manageable condition, alongside BTK and BCL-2 inhibitors for lymphomas and lymphocytic leukaemia. Prior to treatment in Turkey, accredited pathology laboratories perform immunohistochemistry, FISH, or next-generation sequencing to confirm targetable biomarkers.
Targeted therapy before and after: evaluating response and realistic expectations
Response before and after targeted therapy is evaluated using objective radiological criteria (RECIST) rather than outward appearances. Baseline PET-CT or MRI scans record tumour dimensions and metabolic activity. Follow-up scans every 8 to 12 weeks assess whether tumours have shrunk (partial response), resolved (complete response), or stabilised.
Many patients experience symptomatic improvement, such as eased pain or improved breathing, within two to four weeks of starting effective medication. However, in advanced disease, targeted therapy primarily provides disease control rather than an absolute cure. It aims to halt progression, maintain daily quality of life, and prolong survival, with routine blood tests and scans monitoring for signs of treatment resistance.
Who is a suitable candidate for targeted therapy?
Suitable candidates are cancer patients whose biopsy specimens demonstrate a verified, targetable genetic mutation or protein overexpression. Patients must possess adequate liver and kidney function to metabolise and excrete the medication, alongside a sufficient performance status (ECOG 0–2) to tolerate travel and therapy regimens.
Patients are not suitable if molecular profiling reveals no actionable target corresponding to approved drugs. Uncontrolled systemic infections, severe liver failure, or significant cardiac dysfunction may disqualify patients until medically stabilized. Pregnant or breastfeeding women cannot receive targeted therapies due to fetal risks, and severe malabsorption disorders may prevent reliable absorption of oral drugs.
Your trip to Turkey, treatment cycles and daily recovery
A treatment trip to Turkey for targeted therapy follows a structured schedule. Patients arrive in Istanbul, Ankara, or Antalya for two to three days of consultations, blood tests, pathology confirmation, and staging scans. Once the tumour board approves the protocol, oral medication is dispensed or the initial intravenous infusion is administered in a hospital day-care suite.
Most international patients stay 5 to 7 nights for their first cycle to verify drug tolerance before flying home. Daily recovery differs from chemotherapy; severe nausea and hair loss are rare, allowing patients to maintain normal daily routines. Ongoing monitoring involves blood tests every two to four weeks at home to check liver enzymes and blood counts, accompanied by remote oncologist consultations.
Side effects and risks of targeted cancer therapy
Although targeted therapies are more selective than chemotherapy, they still carry documented clinical risks. According to organisations such as the European Society for Medical Oncology (ESMO) and the NHS, common effects include dermatological reactions like acneiform skin rashes and dry skin, particularly with EGFR inhibitors. Gastrointestinal issues such as diarrhoea and mild nausea are also common with oral kinase inhibitors.
Class-specific complications include hypertension and proteinuria with VEGF inhibitors, or reduced cardiac ejection fraction with certain HER2 blockers, necessitating regular blood pressure checks and echocardiograms. Rare but serious risks include interstitial lung disease, liver toxicity, and severe infusion reactions. Accredited oncology teams provide supportive skin care, antihypertensives, and dosage adjustments to manage toxicities safely.
How to choose an oncology centre in Turkey and questions to ask
When choosing a cancer centre in Turkey, ensure the facility holds international accreditation such as Joint Commission International (JCI) and has an on-site multidisciplinary tumour board comprising medical oncologists, surgical specialists, radiologists, and molecular pathologists who review cases collaboratively.
Red flags include clinics guaranteeing cures, prescribing targeted drugs without genetic biomarker verification, quoting fees without medication breakdowns, or lacking 24-hour acute oncology support. You can review how it works for international patient coordination, or request a free quote to submit your medical reports for specialist review.
Questions to ask the oncology clinic
- Which specific biomarker or mutation was identified in my pathology report?
- Is the recommended targeted drug prescribed alone or alongside other therapies?
- How often will I need follow-up scans and blood tests to monitor tumour response?
- What side effects should I watch for, and what supportive treatments are provided?
- How will medication supplies and remote monitoring be managed once I return home?
- Does your hospital have an accredited molecular pathology lab and emergency oncology services?
Hospitals with Oncology in Turkey
Frequently asked questions
Targeted therapy uses precision medicines engineered to block specific genetic mutations or proteins that cancer cells need to grow and survive. Unlike conventional treatments, targeted drugs focus on molecular abnormalities unique to malignant cells, sparing most healthy tissues and slowing or reversing tumour growth.
Yes, extensive clinical trials confirm that targeted therapy effectively shrinks tumours, halts disease progression, and prolongs survival in patients with matching genetic mutations. It is most effective when comprehensive molecular testing confirms an actionable biomarker, though cancer cells can eventually develop secondary resistance.
Approximate costs in Turkey range from €2,500 to €8,000 per month or cycle, compared with €6,000 to €16,000 in the UK and higher in the US. Total costs depend on whether the drug is an established biosimilar or a patented brand, alongside required staging scans.
Before-and-after results are evaluated through baseline and follow-up imaging scans, such as PET-CT or MRI. Effective treatment shows tumour shrinkage or stable disease, often accompanied by reduced pain and improved energy within several weeks, though in advanced cancer it functions as disease control rather than an outright cure.
Chemotherapy attacks all rapidly dividing cells, while targeted therapy selectively inhibits specific mutated proteins on or inside cancer cells. Immunotherapy works differently again by stimulating the patient's own immune system to destroy tumours. Oncologists frequently combine or sequence these treatments based on tumour characteristics.
Side effects depend on the specific drug class. Common effects include acne-like skin rashes, dry skin, diarrhoea, nausea, fatigue, and elevated blood pressure. Most side effects are manageable with supportive medications, skincare regimens, and dose adjustments without stopping treatment.
In early-stage cancers, targeted therapy given as adjuvant care can significantly reduce recurrence risks. In advanced or metastatic disease, it functions as long-term disease control, keeping tumours dormant or shrinking them for months or years until resistance develops, rather than providing a permanent cure.
Eligibility requires a tumour biopsy showing a confirmed actionable genetic mutation or protein target, such as EGFR, HER2, or BRAF. Patients must also have adequate liver and kidney function to process the medication and a satisfactory overall health status to travel.
Most international patients stay 5 to 7 nights for their first treatment cycle. This timeframe allows the medical team to conduct consultations, verify pathology, perform baseline imaging, administer the first dose, and monitor for acute reactions before you travel home.
Targeted therapy has a well-defined safety profile established through international clinical trials. Because it spares most healthy cells, it does not typically cause the severe hair loss or broad bone marrow suppression seen with chemotherapy, though organ function and blood counts require regular monitoring.
Patient stories